Oncotelic Therapeutics, Inc. (OTCMKTS:OTLC – Get Free Report) saw a significant drop in short interest in the month of October. As of October 30th, there was short interest totaling 99,181 shares, a drop of 56.7% from the October 15th total of 229,146 shares. Approximately 0.0% of the company’s shares are sold short. Based on an average daily volume of 738,430 shares, the short-interest ratio is currently 0.1 days.
Oncotelic Therapeutics Stock Performance
Shares of OTLC remained flat at $0.01 during mid-day trading on Tuesday. 85,797 shares of the company’s stock were exchanged, compared to its average volume of 311,463. The firm has a market capitalization of $6.12 million, a PE ratio of 0.02 and a beta of -0.10. The company’s fifty day simple moving average is $0.02 and its two-hundred day simple moving average is $0.04. Oncotelic Therapeutics has a 52 week low of $0.01 and a 52 week high of $0.10. The company has a debt-to-equity ratio of 0.01, a quick ratio of 0.08 and a current ratio of 0.08.
About Oncotelic Therapeutics
Oncotelic Therapeutics, Inc. is a biopharmaceutical company focused on developing treatments for cancer and other serious diseases. Its research includes therapies intended to affect biological pathways involved in tumor growth and the body’s immune response. The company’s lead candidate, OT-101, is an antisense therapy designed to inhibit transforming growth factor beta 2 (TGF-β2). Oncotelic has pursued its development for cancers including glioblastoma and pancreatic cancer; it remains an investigational drug, not an approved treatment.
See Also
- Five stocks we like better than Oncotelic Therapeutics
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
- Tyson Foods’ Earnings Beat Hides a Warning for Consumer Staples Dividend Investors
- 3 Stocks in an Overlooked Corner of Infrastructure With Hundreds of Billions at Stake
Receive News & Ratings for Oncotelic Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncotelic Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
